R Squared’s Dianthus Therapeutics DNTH Stock Holding History

R Squared’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,200	Closed	-$26.2K	–	621
2024 Q4	$26.2K	Buy	+1,200	New	+$30.9K	0.03%	762

Other funds holding DNTH

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

R Squared's DNTH Position: Q1 2025 in Review

R Squared sold out of Dianthus Therapeutics (DNTH) in Q1 2025, closing a stake of 1,200 shares — an estimated $26.2K sold.

R Squared first reported a position in DNTH in Q4 2024 and held it in 1 quarter. The position peaked at $26.2K in Q4 2024. 98 funds tracked by Wall St. Rank hold DNTH as of Q1 2025.

R Squared reported no remaining Dianthus Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,200 Dianthus Therapeutics shares in Q1 2025, an estimated $26.2K.
R Squared first reported a position in Dianthus Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Dianthus Therapeutics position peaked at $26.2K in Q4 2024.
98 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.